Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31836199

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2020 Jan 11
First author
Mateos MV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Jan 11;395(10218):94-96. doi: 10.1016/S0140-6736(19)33063-6.
    note
    Source null
    related pmid
    31836198
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Feb;17(2):67. doi: 10.1038/s41571-019-0321-2.
    note
    Source null
    related pmid
    31862988
    relationship
    Comment in

Authors and identifiers

  1. name
    Mateos MV
    type
    Author
  2. name
    Cavo M
    type
    Author
  3. name
    Blade J
    type
    Author
  4. name
    Dimopoulos MA
    type
    Author
  5. name
    Suzuki K
    type
    Author
  6. name
    Jakubowiak A
    type
    Author
  7. name
    Knop S
    type
    Author
  8. name
    Doyen C
    type
    Author
  9. name
    Lucio P
    type
    Author
  10. name
    Nagy Z
    type
    Author
  11. name
    Pour L
    type
    Author
  12. name
    Cook M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Mateos MV
    type
    Author
  2. name
    Cavo M
    type
    Author
  3. name
    Blade J
    type
    Author
  4. name
    Dimopoulos MA
    type
    Author
  5. name
    Suzuki K
    type
    Author
  6. name
    Jakubowiak A
    type
    Author
  7. name
    Knop S
    type
    Author
  8. name
    Doyen C
    type
    Author
  9. name
    Lucio P
    type
    Author
  10. name
    Nagy Z
    type
    Author
  11. name
    Pour L
    type
    Author
  12. name
    Cook M
    type
    Author
bibliography ids
  1. nci-bib-23e7952905d51cde102ba9c6
book metadata
content sha256
9b877e749100587d2b347429d9bcaedd33706f054fab3b068a67fb8a6dacde6e
document type
citation
dois
  1. 10.1016/S0140-6736(19)32956-3
electronic publication date
display
2019 Dec 10
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31836199
immutable id
pubmed:31836199@9b877e749100587d2b347429d9bcaedd33706f054fab3b068a67fb8a6dacde6e
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10218
name
Lancet (London, England)
nlm unique id
2985213R
pages
132-141
volume
395
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Jan 11;395(10218):94-96. doi: 10.1016/S0140-6736(19)33063-6.
    note
    Source null
    related pmid
    31836198
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Feb;17(2):67. doi: 10.1038/s41571-019-0321-2.
    note
    Source null
    related pmid
    31862988
    relationship
    Comment in
outcomes validated
false
pmid
31836199
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
4d5b42fdb67cc0c8195e40dd81441138174325e63256fb2487df92276658460d
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Jan 11
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31836199/
title
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice